Opthea to present data at Clinical Trials at the Summit 2024

(Image credit: AdobeStock/Jason)

At the upcoming fourth annual Clinical Trials at the Summit (CTS) Meeting, held in Park City, Utah on June 8, 2024, Opthea Limited announced it will be making several presentations covering a wide range of topics.

Clinical Trials at the Summit brings together experts from around the world to discuss ongoing clinical trials and the latest data, with the intention of furthering vitreoretinal care.

Presentations from the company will include 2 scientific presentations related to the sozinibercept (OPT-302) clinical trial program. The COAST and ShORe trials, designed to assess the safety and superior efficacy of sozinibercept (OPT-302) along with standard-of-care anti-VEGF-A therapies in the treatment of patients with wet AMD, just recently completed enrollment. The 2 scientific presentations will be given by Megan Baldwin, PhD, MAICD, Founder, chief innovation officer and executive director, Opthea, and Julie Clark, MD, senior vice president of clinical development, Opthea.

Frederic Guerard, PharmD, chief executive officer of Opthea, will also participate in a panel discussing the challenges of bringing new treatment options to market.

The CTS meeting will also feature panels and discussions on a range of topics including, AMD, gene therapy, OCT, trial updates and more.